GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synaptogenix Inc (NAS:SNPX) » Definitions » Equity-to-Asset

Synaptogenix (Synaptogenix) Equity-to-Asset : 0.78 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Synaptogenix Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Synaptogenix's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $22.88 Mil. Synaptogenix's Total Assets for the quarter that ended in Mar. 2024 was $29.40 Mil.

The historical rank and industry rank for Synaptogenix's Equity-to-Asset or its related term are showing as below:

SNPX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.76   Med: 0.94   Max: 0.98
Current: 0.78

During the past 5 years, the highest Equity to Asset Ratio of Synaptogenix was 0.98. The lowest was 0.76. And the median was 0.94.

SNPX's Equity-to-Asset is ranked better than
63.82% of 1556 companies
in the Biotechnology industry
Industry Median: 0.67 vs SNPX: 0.78

Synaptogenix Equity-to-Asset Historical Data

The historical data trend for Synaptogenix's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synaptogenix Equity-to-Asset Chart

Synaptogenix Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
0.97 0.76 0.94 0.92 0.82

Synaptogenix Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.94 0.81 0.88 0.82 0.78

Competitive Comparison of Synaptogenix's Equity-to-Asset

For the Biotechnology subindustry, Synaptogenix's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synaptogenix's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synaptogenix's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Synaptogenix's Equity-to-Asset falls into.



Synaptogenix Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Synaptogenix's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=25.584/31.114
=

Synaptogenix's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=22.877/29.399
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Synaptogenix  (NAS:SNPX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Synaptogenix Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Synaptogenix's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Synaptogenix (Synaptogenix) Business Description

Traded in Other Exchanges
N/A
Address
1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
Executives
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Robert Weinstein officer: Chief Financial Officer 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Bruce Bernstein director 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
Jonathan Schechter director C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
William S. Singer director C/O KIRKLAND & ELLIS LLP, 300 NORTH LASALLE, CHICAGO IL 60654
Daniel L. Alkon director, officer: Chief Scientific Officer C/O NEUROTROPE, INE., 205 EAST 42ND STREET - 20TH FLOOR, NEW YORK NY 10017
Alan J Tuchman director, officer: Chief Executive Officer 18 SYCAMORE ROAD, MAHOPAC NY 10541
George Perry director C/O NEUROTROPE, INC., 205 EAST 42ND STREET, 17TH FLOOR, NEW YORK NY 10010

Synaptogenix (Synaptogenix) Headlines

From GuruFocus

Synaptogenix to Present at the Cell Symposium

By PRNewswire PRNewswire 07-06-2022